Synapse - Lindsey Roeker

Results (142)

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Journal Article

Eyre, T. A.; Roeker, L. E.; Fox, C. P.; Gohill, S. H.; Walewska, R.; Walter, H. S.; Forconi, F.; Broom, A.; Arumainathan, A.; Brander, D. M.; more...
British Journal of Haematology (2020)

Fulltext@MSK | Save

Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: A retrospective analysis of real world patients

Meeting Abstract

Yazdy, M. S.; Mato, A. R.; Roeker, L. E.; Jarral, U.; Ujjani, C. S.; Shadman, M.; Skarbnik, A.; Whitaker, K. J.; Deonarine, I.; Kabel, C. C.; more...
Blood (2019)

Fulltext@MSK | Save

Veneto-STOP study: Sequential assessment of minimal residual disease by next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients

Meeting Abstract

Ujjani, C. S.; Roeker, L. E.; Shadman, M.; Whitaker, K. J.; Jacob, A. P.; Geyer, M. B.; Dorsey, C.; Zelenetz, A. D.; Mato, A. R.
Blood (2019)

Fulltext@MSK | Save

Treatment discontinuation patterns for patients with CLL in the real-world settings: Results from a multi-center study

Meeting Abstract

Shadman, M.; Sail, K.; Manzoor, B. S.; Yazdy, M. S.; Hill, B. T.; Tuncer, H. H.; Allan, J. N.; Ujjani, C. S.; Emechebe, N.; Kamalakar, R.; more...
Blood (2019)

Fulltext@MSK | Save

Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents

Meeting Abstract

Roeker, L. E.; Brown, J. R.; Dreger, P.; Lahoud, O. B.; Eyre, T. A.; Brander, D. M.; Skarbnik, A.; Coombs, C. C.; Kim, H. T.; Manchini, S. T.; more...
Blood (2019)

Fulltext@MSK | Save

Treatment sequences and outcomes of patients with CLL treated with venetoclax and other novel agents post introduction of novel therapies

Meeting Abstract

Mato, A. R.; Sail, K.; Yazdy, M. S.; Hill, B. T.; Shadman, M.; Manzoor, B. S.; Tuncer, H. H.; Allan, J. N.; Ujjani, C. S.; Sharmokh, S.; more...
Blood (2019)

Fulltext@MSK | Save

Time to second treatment as a proxy for overall survival in CLL/SLL: Identifying risk factors to help guide treatment selection

Meeting Abstract

Bantilan, K. S.; Soumerai, J. D.; Roeker, L. E.; Mato, A. R.; Zelenetz, A. D.
Blood (2019)

Fulltext@MSK | Save

Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies

Meeting Abstract

Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; more...
Blood (2019)

Fulltext@MSK | Save

A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas